Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function

Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function

The optimal regimens of cefmetazole and flomoxef for the treatment of urinary tract infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales are not well defined. Our study found that the pharmacokinetic/pharmacodynamic targets for cefmetazole and flomoxef were 70% T >...

Full description

Bibliographic Details
Main Authors: Doi, Y. (Author), Hamada, Y. (Author), Hayakawa, K. (Author), Kasai, H. (Author), Matsumura, Y. (Author), Suzuki-Ito, M. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
adult
antimicrobial stewardship
Article
bactericidal activity
body weight
cefmetazole
clinical article
controlled study
creatinine clearance
Enterobacterales
Escherichia coli
extended spectrum beta lactamase
female
flomoxef
human
kidney disease
kidney function
Klebsiella oxytoca
Klebsiella pneumoniae
male
minimum inhibitory concentration
Monte Carlo method
Monte Carlo simulations
nonhuman
pharmacodynamics
pharmacokinetic parameters
pharmacokinetics
pharmacokinetics/pharmacodynamics
probability
Proteus mirabilis
urinary tract infection
volume of distribution
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items